New York Pharma Forum Elects Blaine McKee, Genzyme, as President

New York Pharma Forum Elects Blaine McKee, Genzyme, as President
NEW YORK--(BUSINESS WIRE)--The New York Pharma Forum (NYPF), a leading non-profit association for international biopharmaceutical corporations, announced the election of Blaine McKee, Ph.D. as president. Dr. McKee is Senior Vice President of Strategic Development for Oncology, Transplant and Multiple Sclerosis at Genzyme Corporation. He was elected at a meeting of the NYPF board of directors held yesterday.

In addition, the following officers were also elected: Vice President: Thomas Heffner, Ph.D., Executive Director, Worldwide Business Development, Pfizer Inc.; Secretary: Catherine Sazdanoff, Vice President, Corporate Development Takeda Pharmaceuticals International; Treasurer: Nobuhiko Tamura, Executive Vice President, Chief Scientific Officer, Sunovion Pharmaceuticals Inc.

"I'm honored that my colleagues at New York Pharma Forum have chosen me to lead the organization," commented Dr. McKee. "The NYPF is a terrific community of companies and professionals committed to enhancing international relationships within the biopharma industry, particularly relationships between Japanese, U.S. and other multinational companies. For more than 20 years, the Forum has provided outstanding resources for educational and networking opportunities. We will continue our work of examining issues most important to our industry, while at the same time offering members new and exciting insight into its future."

Dr. McKee joined Genzyme Corporation in 1996. He holds a Ph.D. in synthetic organic chemistry from Massachusetts Institute of Technology, as well as an MBA from the MIT Sloan School of Management and a Bachelor of Science degree from Colorado State University. He has served on the NYPF Board of Directors for over five years, and has previously served as Vice President and Secretary of the Board.

About New York Pharma Forum

New York Pharma Forum Inc. is a non-profit organization intended to encourage dialogue among U.S., Japanese and other international biopharmaceutical executives and business and financial professionals on global issues of common interest. Members gain access to critical information on business, policy and technology issues important to the future of the global healthcare industry. For more information about the organization, visit http://www.nypharmaforum.org.


Contacts
New York Pharma Forum
Dave Heffernan, +1-212-583-1043, Ext. 14
[email protected]


 

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.